

Resource Summary Report

Generated by [RRID](#) on Jul 31, 2026

Anti-PD-L1 Antibody

RRID:AB_2687878

Type: Antibody

Proper Citation

Abcam Cat# ab205921, RRID:AB_2687878

Antibody Information

URL: http://antibodyregistry.org/AB_2687878

Proper Citation: Abcam Cat# ab205921, RRID:AB_2687878

Target Antigen: PD-L1

Host Organism: rabbit

Clonality: monoclonal

Comments: Image validation available for IHC-P, WB, Flow Cyt in MDS.

Antibody Name: Anti-PD-L1 Antibody

Description: This monoclonal targets PD-L1

Target Organism: human

Clone ID: 28-8

Antibody ID: AB_2687878

Vendor: Abcam

Catalog Number: ab205921

Record Creation Time: 20250820T011003+0000

Record Last Update: 20250820T101237+0000

Ratings and Alerts

- Used for immunofluorescence microscopy assay by the Human Islet Research Network community. Contact(s): [Decio Eizirik](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for Anti-PD-L1 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 37 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Liu SX, et al. (2025) Interferon-responsive HEVs drive tumor tertiary lymphoid structure formation and predict immunotherapy response in nasopharyngeal carcinoma. Cell reports. Medicine, 6(7), 102200.

Hu SW, et al. (2025) Co-targeting CDK4/6 enhances anti-cancer activity and alleviates immune-related adverse events of anti-PD-1 antibody for breast cancer. Cell reports. Medicine, 6(11), 102429.

Luo B, et al. (2025) Resveratrol amplifies the anti-tumor effect of γ -PD-1 by altering the intestinal microbiome and PGD2 content. Gut microbes, 17(1), 2447821.

Wang JM, et al. (2025) KIF26B promotes bladder cancer progression via activating Wnt/ β -catenin signaling in a TRAF2-dependent pathway. Cell reports, 44(5), 115595.

Wang W, et al. (2025) BET inhibitor in combination with BCG vaccine enhances antitumor efficacy and orchestrates T cell reprogramming for melanoma. Cell reports. Medicine, 6(3), 101995.

Chen D, et al. (2025) Efficacy and safety of adjuvant TTFIELDS plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study. Med (New York, N.Y.), 6(9), 100708.

Wang Q, et al. (2024) Benzosciprin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3. Cell reports. Medicine, 5(2), 101357.

Wang X, et al. (2024) Cell-intrinsic PD-L1 ablation sustains effector CD8⁺ T cell responses and promotes antitumor T cell therapy. Cell reports, 43(2), 113712.

Jin N, et al. (2024) Multispectral fluorescence imaging of EGFR and PD-L1 for precision detection of oral squamous cell carcinoma: a preclinical and clinical study. BMC medicine, 22(1), 342.

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8⁺ T cells via JAK2/STAT3 pathway. Cell genomics, 4(10), 100659.

Lin F, et al. (2024) Multimodal targeting chimeras enable integrated immunotherapy leveraging tumor-immune microenvironment. *Cell*, 187(26), 7470.

Su X, et al. (2024) The role of JMJD2A in immune evasion and malignant behavior of esophageal squamous cell carcinoma. *International immunopharmacology*, 137, 112401.

Nokin MJ, et al. (2024) In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma. *Cell reports. Medicine*, 5(8), 101663.

Knisely A, et al. (2024) Phase 1b study of batiraxcept in combination with durvalumab in patients with platinum-resistant ovarian cancer. *iScience*, 27(5), 109801.

Chen Z, et al. (2024) SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8+ T cell apoptosis to promote immune evasion. *Oncoimmunology*, 13(1), 2376264.

Li J, et al. (2024) Amitriptyline revitalizes ICB response via dually inhibiting Kyn/Indole and 5-HT pathways of tryptophan metabolism in ovarian cancer. *iScience*, 27(12), 111488.

Wang H, et al. (2024) Nucleo-cytosolic acetyl-CoA drives tumor immune evasion by regulating PD-L1 in melanoma. *Cell reports*, 43(12), 115015.

Zhang B, et al. (2023) Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. *Cell reports. Medicine*, 4(12), 101301.

Wang Z, et al. (2023) Extracellular vesicles in fatty liver promote a metastatic tumor microenvironment. *Cell metabolism*, 35(7), 1209.

Huang Q, et al. (2023) MTFR2 shapes a barrier of immune microenvironment in hepatocellular carcinoma. *iScience*, 26(1), 105095.